021-51111890
购物车（）
sales@molnova.cn
Lenvatinib
CAS No. 417716-92-8
Lenvatinib ( E7080 | E-7080 | E 7080 )
产品货号. M14427 CAS No. 417716-92-8
Lenvatinib (E7080) 是一种多靶点激酶抑制剂，在无细胞测定中对 VEGFR2/VEGFR3/VEGFR1/FGFR1 的 IC50 为 4/5.2/22/46 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥411 | 有现货 |
|
| 5MG | ￥508 | 有现货 |
|
| 10MG | ￥816 | 有现货 |
|
| 25MG | ￥1442 | 有现货 |
|
| 50MG | ￥2390 | 有现货 |
|
| 100MG | ￥2952 | 有现货 |
|
| 500MG | ￥4887 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Lenvatinib
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Lenvatinib (E7080) 是一种多靶点激酶抑制剂，在无细胞测定中对 VEGFR2/VEGFR3/VEGFR1/FGFR1 的 IC50 为 4/5.2/22/46 nM。
-
产品描述Lenvatinib (E7080) is a multitargeted kinase inhibitor with IC50s of 4/5.2/22/46 nM for VEGFR2/VEGFR3/VEGFR1/FGFR1 in cell free assays; also inhibits PDGFR, Kit with IC50< 100 nM; suppresses the phosphorylation of VEGF receptor-2 and FGF receptor 1 and inhibits proliferation of endothelial cellin vitro; orally active.Kidney Cancer Approved(In Vitro):Lenvatinib (E7080) has IC50s of 4, 5.2, 22 nM for VEGFR2 (KDR), VEGFR3 (Flt-4), and VEGFR1 (Flt-1), respectively. Lenvatinib inhibits PDGFRα, PDGFRβ, FGFR1, and KIT with IC50s of 51, 39, 46, and 100 nM, respectively.(In Vivo):Lenvatinib (E7080) (100 mg/kg, p.o.) significantly inhibits local tumor growth at the m.f.p., and at the end of treatment, Lenvatinib mesylate also significantly inhibits metastasis to both regional lymph nodes and distant lung.Lenvatinib (E7080) inhibits the growth of H146 tumor at 30 and 100 mg/kg (BID, QDx21) in a dose-dependent manner and causes tumor regression at 100 mg/kg in H146 xenograft model. IHC analysis with anti-CD31 antibody shows that lenvatinib at 100 mg/kg decreases microvessel density more than anti-VEGF antibody and STI571 treatment.
-
体外实验Lenvatinib (E7080) has IC50s of 4, 5.2, 22 nM for VEGFR2 (KDR), VEGFR3 (Flt-4), and VEGFR1 (Flt-1), respectively. Lenvatinib inhibits PDGFRα, PDGFRβ, FGFR1, and KIT with IC50s of 51, 39, 46, and 100 nM, respectively.
-
体内实验Lenvatinib (E7080) (100 mg/kg, p.o.) significantly inhibits local tumor growth at the m.f.p., and at the end of treatment, Lenvatinib mesylate also significantly inhibits metastasis to both regional lymph nodes and distant lung.Lenvatinib (E7080) inhibits the growth of H146 tumor at 30 and 100 mg/kg (BID, QDx21) in a dose-dependent manner and causes tumor regression at 100 mg/kg in H146 xenograft model. IHC analysis with anti-CD31 antibody shows that lenvatinib at 100 mg/kg decreases microvessel density more than anti-VEGF antibody and STI571 treatment.
-
同义词E7080 | E-7080 | E 7080
-
通路Angiogenesis
-
靶点VEGFR
-
受体FGFR1|PDGFRβ|VEGFR1/FLT1|VEGFR2/KDR|VEGFR3/FLT4
-
研究领域Cancer
-
适应症Kidney Cancer
化学信息
-
CAS Number417716-92-8
-
分子量426.853
-
分子式C21H19ClN4O4
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESCOC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4CC4)C=C3)=C2C=C1C(N)=O
-
化学全称6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Matsui J, et al. Int J Cancer. 2008 Feb 1;122(3):664-71.
2. Matsui J, et al. Clin Cancer Res. 2008 Sep 1;14(17):5459-65.
3. Ikuta K, et al. Clin Cancer Res. 2009 Dec 1;15(23):7229-37.
产品手册
关联产品
-
BIBF 1202
BIBF 1202 是一种 VEGFR2 激酶抑制剂 (IC50 = 62 nM)。
-
Telatinib
一种口服活性小分子抑制剂，用于生化测定中的 VEGFR-2 (IC50=6 nM)、VEGFR-3 (IC50=4 nM)、PDEGFRα (IC50=15 nM) 和 c-Kit (IC50=1 nM)。
-
(E)-FeCP-oxindole
(Z)-FeCP-oxindole 是一种选择性的人血管内皮细胞生长因子受体 2 (VEGFR2) 抑制剂，其 IC50 值为 200 nM。(Z)-FeCP-oxindole 在 10 μM 时可以显著抑制 VEGFR1 和 PDGFRa 或 b。(Z)-FeCP-oxindole 具有一定的抗癌活性，作用于 B16 鼠黑色素瘤系的 IC50 < 1 μM。
